Danaher Corporation $DHR Shares Bought by Harvest Portfolios Group Inc.

Harvest Portfolios Group Inc. increased its position in Danaher Corporation (NYSE:DHR) by 13.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 280,648 shares of the conglomerate’s stock after acquiring an additional 32,599 shares during the period. Danaher makes up about 1.3% of Harvest Portfolios Group Inc.’s investment portfolio, making the stock its 27th biggest position. Harvest Portfolios Group Inc.’s holdings in Danaher were worth $55,439,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Boyd Watterson Asset Management LLC OH raised its stake in shares of Danaher by 2.1% during the 2nd quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate’s stock worth $499,000 after buying an additional 51 shares during the last quarter. Worth Financial Advisory Group LLC increased its holdings in Danaher by 4.6% during the 2nd quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock valued at $236,000 after acquiring an additional 53 shares in the last quarter. 1834 Investment Advisors Co. raised its position in Danaher by 3.3% during the first quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate’s stock worth $342,000 after acquiring an additional 54 shares during the last quarter. Bruce G. Allen Investments LLC lifted its holdings in shares of Danaher by 13.1% in the second quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock valued at $92,000 after purchasing an additional 54 shares in the last quarter. Finally, Texas Bank & Trust Co grew its position in shares of Danaher by 1.6% in the second quarter. Texas Bank & Trust Co now owns 3,567 shares of the conglomerate’s stock valued at $705,000 after purchasing an additional 55 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on DHR shares. Guggenheim reaffirmed a “buy” rating and issued a $250.00 target price on shares of Danaher in a research note on Wednesday, July 23rd. JPMorgan Chase & Co. boosted their price target on Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research report on Sunday, November 2nd. Deutsche Bank Aktiengesellschaft upped their target price on shares of Danaher from $235.00 to $250.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. Finally, Rothschild & Co Redburn reaffirmed a “neutral” rating and set a $220.00 price target (down from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. Eighteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $243.39.

Danaher Price Performance

DHR opened at $210.97 on Friday. The company has a 50 day moving average of $203.94 and a two-hundred day moving average of $200.14. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $258.23. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. The company has a market cap of $149.02 billion, a P/E ratio of 43.50, a P/E/G ratio of 3.28 and a beta of 0.81.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.17. The company had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.71 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s dividend payout ratio (DPR) is currently 26.39%.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.